10/15/2026

Janusmed sex and gender

Janusmed sex and gender – acamprosate

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Acamprosate

Acamprosate

Class : A

Show all info

Print

Contact us

  1. Global Burden of Disease Sex Differences Visualization. Seattle, WA: Institute for Health Metrics and Evaluation (IHME). 2023 [cited 2026-05-05.]

  2. Statistikdatabas för diagnoser. Stockholm: Socialstyrelsen. 2024 [cited 2026-05-05.]

  3. Statistikdatabas för dödsorsaker. Stockholm: Socialstyrelsen. 2024 [cited 2026-05-05.]

  4. Saivin S, Hulot T, Chabac S, Potgieter A, Durbin P, Houin G. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 1998 Nov;35(5):331-45

  5. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - CAMPRAL (acamprosate). US Food and Drug Administration [www]. [updated 2004-07-29, cited 2016-04-01].

  6. Campral (acamprosate). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2026-05-22, cited 2026-08-24]

  7. Läkemedelsboken. Uppsala: Läkemedelsverket; 2026.

  8. Mason BJ, Lehert P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res. 2012;36:497-508.

  9. Verheul R, Lehert P, Geerlings PJ, Koeter MW, van den Brink W. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology (Berl). 2005;178:167-73.

  10. Gross CM, Spiegelhalder K, Mercak J, Feige B, Langosch JM. Predictability of alcohol relapse by hippocampal volumetry and psychometric variables. Psychiatry Res. 2013;212:14-8.

  11. Icro Maremmani AG, Bacciardi S, Rovai L, Rugani F, Massimetti E, Gazzarrini D et al. Six-month outcome in bipolar spectrum alcoholics treated with acamprosate after detoxification: a retrospective study. Int J Environ Res Public Health. 2014;11:12983-96.

  12. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]

  1. Global Burden of Disease Sex Differences Visualization. Seattle, WA: Institute for Health Metrics and Evaluation (IHME). 2023 [cited 2026-05-05.]
  2. Statistikdatabas för diagnoser. Stockholm: Socialstyrelsen. 2024 [cited 2026-05-05.]
  3. Statistikdatabas för dödsorsaker. Stockholm: Socialstyrelsen. 2024 [cited 2026-05-05.]
  4. Saivin S, Hulot T, Chabac S, Potgieter A, Durbin P, Houin G. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 1998 Nov;35(5):331-45
  5. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - CAMPRAL (acamprosate). US Food and Drug Administration [www]. [updated 2004-07-29, cited 2016-04-01].
  6. Campral (acamprosate). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2026-05-22, cited 2026-08-24]
  7. Läkemedelsboken. Uppsala: Läkemedelsverket; 2026.
  8. Mason BJ, Lehert P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res. 2012;36:497-508.
  9. Verheul R, Lehert P, Geerlings PJ, Koeter MW, van den Brink W. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology (Berl). 2005;178:167-73.
  10. Gross CM, Spiegelhalder K, Mercak J, Feige B, Langosch JM. Predictability of alcohol relapse by hippocampal volumetry and psychometric variables. Psychiatry Res. 2013;212:14-8.
  11. Icro Maremmani AG, Bacciardi S, Rovai L, Rugani F, Massimetti E, Gazzarrini D et al. Six-month outcome in bipolar spectrum alcoholics treated with acamprosate after detoxification: a retrospective study. Int J Environ Res Public Health. 2014;11:12983-96.
  12. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]